These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 18263681

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [The variability of clinical presentation of chronic obstructive pulmonary disease in patients with hereditary alpha-1 antitrypsin deficiency].
    Kuca P, Kamiński D, Campbell E, Kołakowski J, Goljan-Geremek A, Puścińska E, Bieleń P, Nowiński A, Wojda E, Hawryłkiewicz I, Sliwiński P, Górecka D.
    Pneumonol Alergol Pol; 2004; 72(9-10):420-3. PubMed ID: 16021998
    [Abstract] [Full Text] [Related]

  • 24. COPD in individuals with the PiMZ alpha-1 antitrypsin genotype.
    Al Ashry HS, Strange C.
    Eur Respir Rev; 2017 Dec 31; 26(146):. PubMed ID: 29070580
    [Abstract] [Full Text] [Related]

  • 25. Impaired Carbon Monoxide Diffusing Capacity is the strongest lung function predictor of decline in 12 minute-walking distance in COPD; a 5-year follow-up study.
    Farkhooy A, Janson C, Arnardóttir RH, Emtner M, Hedenström H, Malinovschi A.
    COPD; 2015 Jun 31; 12(3):240-8. PubMed ID: 25208266
    [Abstract] [Full Text] [Related]

  • 26. Long-term results after lung volume reduction surgery in patients with alpha1-antitrypsin deficiency.
    Tutic M, Bloch KE, Lardinois D, Brack T, Russi EW, Weder W.
    J Thorac Cardiovasc Surg; 2004 Sep 31; 128(3):408-13. PubMed ID: 15354100
    [Abstract] [Full Text] [Related]

  • 27. [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
    Liu QX, Zheng JP, Xie YQ, Guan WJ, Jiang CY, An JY, Yu XX, Liu WT, Gao Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul 31; 36(7):510-5. PubMed ID: 24262087
    [Abstract] [Full Text] [Related]

  • 28. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
    Stockley RA, Edgar RG, Pillai A, Turner AM.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 31; 11():1745-56. PubMed ID: 27536086
    [Abstract] [Full Text] [Related]

  • 29. Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD.
    Díaz AA, Pinto-Plata V, Hernández C, Peña J, Ramos C, Díaz JC, Klaassen J, Patino CM, Saldías F, Díaz O.
    Respir Med; 2015 Jul 31; 109(7):882-9. PubMed ID: 25952774
    [Abstract] [Full Text] [Related]

  • 30. The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.
    Tanash HA, Nystedt-Düzakin M, Montero LC, Sveger T, Piitulainen E.
    Ann Am Thorac Soc; 2015 Jun 31; 12(6):807-12. PubMed ID: 25803183
    [Abstract] [Full Text] [Related]

  • 31. Applicability of the single-breath carbon monoxide diffusing capacity in a Norwegian Community Study.
    Welle I, Eide GE, Bakke P, Gulsvik A.
    Am J Respir Crit Care Med; 1998 Dec 31; 158(6):1745-50. PubMed ID: 9847262
    [Abstract] [Full Text] [Related]

  • 32. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.
    Thun GA, Ferrarotti I, Imboden M, Rochat T, Gerbase M, Kronenberg F, Bridevaux PO, Zemp E, Zorzetto M, Ottaviani S, Russi EW, Luisetti M, Probst-Hensch NM.
    PLoS One; 2012 Dec 31; 7(8):e42728. PubMed ID: 22912729
    [Abstract] [Full Text] [Related]

  • 33. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.
    Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG.
    Am Rev Respir Dis; 1988 Aug 31; 138(2):327-36. PubMed ID: 3264124
    [Abstract] [Full Text] [Related]

  • 34. Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?
    Seersholm N, Kok-Jensen A.
    Respir Med; 1998 Feb 31; 92(2):241-5. PubMed ID: 9616519
    [Abstract] [Full Text] [Related]

  • 35. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema.
    Morrison NJ, Abboud RT, Ramadan F, Miller RR, Gibson NN, Evans KG, Nelems B, Müller NL.
    Am Rev Respir Dis; 1989 May 31; 139(5):1179-87. PubMed ID: 2712446
    [Abstract] [Full Text] [Related]

  • 36. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects.
    Bruce RM, Cohen BH, Diamond EL, Fallat RJ, Knudson RJ, Lebowitz MD, Mittman C, Patterson CD, Tockman MS.
    Am Rev Respir Dis; 1984 Sep 31; 130(3):386-90. PubMed ID: 6332562
    [Abstract] [Full Text] [Related]

  • 37. Lung diffusing capacity for nitric oxide and carbon monoxide: dependence on breath-hold time.
    Dressel H, Filser L, Fischer R, de la Motte D, Steinhaeusser W, Huber RM, Nowak D, Jörres RA.
    Chest; 2008 May 31; 133(5):1149-54. PubMed ID: 18263682
    [Abstract] [Full Text] [Related]

  • 38. Alpha-1 antitrypsin Null mutations and severity of emphysema.
    Fregonese L, Stolk J, Frants RR, Veldhuisen B.
    Respir Med; 2008 Jun 31; 102(6):876-84. PubMed ID: 18353624
    [Abstract] [Full Text] [Related]

  • 39. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
    Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J.
    Am J Respir Crit Care Med; 1999 Nov 31; 160(5 Pt 1):1468-72. PubMed ID: 10556107
    [Abstract] [Full Text] [Related]

  • 40. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates.
    Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ.
    Ann Intern Med; 1989 Dec 15; 111(12):982-91. PubMed ID: 2596778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.